Zacks Investment Research Lowers Adamas Pharmaceuticals (ADMS) to Hold
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
A number of other brokerages also recently weighed in on ADMS. ValuEngine downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Mizuho restated a “sell” rating and issued a $5.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, April 24th. Piper Jaffray Companies set a $23.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 5th. HC Wainwright set a $40.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 5th. Finally, Northland Securities restated a “buy” rating and issued a $28.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, March 5th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $20.25.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.13) by $0.05. The firm had revenue of $11.67 million during the quarter, compared to the consensus estimate of $12.78 million. Adamas Pharmaceuticals had a negative net margin of 291.22% and a negative return on equity of 122.40%. Equities analysts expect that Adamas Pharmaceuticals will post -3.87 EPS for the current year.
In other news, CEO Gregory T. Went sold 6,319 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total transaction of $50,488.81. Following the completion of the sale, the chief executive officer now directly owns 176,291 shares in the company, valued at $1,408,565.09. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 8,361 shares of company stock valued at $66,816. 24.90% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of ADMS. BNP Paribas Arbitrage SA acquired a new stake in Adamas Pharmaceuticals in the first quarter worth $33,000. PNC Financial Services Group Inc. acquired a new stake in Adamas Pharmaceuticals in the first quarter worth $43,000. First Mercantile Trust Co. grew its holdings in Adamas Pharmaceuticals by 43.2% in the fourth quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 1,740 shares during the period. Advisor Group Inc. grew its holdings in Adamas Pharmaceuticals by 252.0% in the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 4,510 shares during the period. Finally, Jefferies Group LLC acquired a new stake in Adamas Pharmaceuticals in the first quarter worth $107,000. Institutional investors own 88.03% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
See Also: Exchange-Traded Funds (ETFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.